anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a new polyamino acid derivative having such a structure that a plurality of amino acids are mutually bound via the amino group&#39;s nitrogen atom through crosslinking group, and useful in various applications such as dispersants, metal ion chelating agents and rustproofing agents. SOLUTION: This new polyamino acid derivative is such one that four or more amino acids are mutually bound via the amino group&#39;s nitrogen atom through crosslinking group; wherein the crosslinking group is pref. hydroxyl group and/or an alkylene group optionally having ether linkage in the carbon chain [e.g. a group of formula I ((k) is an integer of 1-10)], and this derivative is pref. a derivative of formula II (B is an amino acid side chain; M is H or a counterion; (n) is an integer of &gt;=4). The new polyamino acid derivative is obtained by reaction between (x) mol of epichlorohydrin and/or (y) mol of a polyepoxy compound having (z) epoxy functional groups and an amino acid at [2/3×(x+y×z/2) to 4/3×(x+y×z/2) mol.
&lt;P&gt;PROBLEM TO BE SOLVED: To prepare a cosmetic in which raw materials difficultly soluble both in an oily ingredient and in an aqueous ingredient are uniformly emulsified or dispersed.  &lt;P&gt;SOLUTION: This cosmetic comprises (1) a compound represented by formula (1) and (2) a triterpene derivative and/or a sphingosine derivative. It is desirable that the compound represented by formula (1) is phenoxyethanol or phenethyl alcohol. It is desirable that the triterepene derivative is at least one member selected from among a triterepenol glycoside, a triterpene acid, and a triterpene acid ester. It is desirable that the sphigosine derivative is a sphingoglycolipid or a sphingophospholipid. It is desirable that the cosmetic is in a form not substantially containing an alcohol. In formula (1), A is oxygen atom or methylene group; and R is a 1 to 4C alkylene group.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain a cell-activating agent containing the extract of a plant belonging to the genus Boehmeria and having a testosterone-5α-reductase (referred to as TSR)-inhibiting activity, an epidermal moisture-retaining activity, a cell-proliferating activity or their combined activities. SOLUTION: This cell-activating agent contains the solvent extract of a plant to the genus Boehmeria as an active ingredient in an amount of &gt;=0.0001wt.%, especially 0.0001-20wt.%, converted into the solvent extract. The plant includes Boehmeria longispica Steud, Boehmeria tricuspis Makino and Boehmeria nivea Gaud, and the extraction solution is obtained by immersing the desired site of the plant in a solvent (e.g. acetone). The cell-activating agent is low toxic, exhibits a vasodilator activity, a tyrosinase-inhabiting activity, a SOD-like activity, and an antioxidizing activity in addition to the above- described activity, and can be utilized for cosmetics, especially hair-growing agents, and for various kinds of medicines and quasi drugs. The hair-growing agents safely inhibit TSR causing the falling of hair and give an excellent hair-growing effect.
An active substance which retards the development of sex is extracted from animal or human fluids, such as blood, lymph, serum, urine, by processes of concentration and purification controlled by tests on experimental animals.  The substance differs from known hormones such as that obtained from the anterior tube of the hypophysis which have an indirect retarding action on parts of the sex functions due to the formation of lipoid substances in the ovary.  Accordingly, the hypophysis and the corpus luteum, in which their specific hormones predominate, are not suitable sources of the new hormone, and the tests used in controlling the extraction, such as the effect on the rut of female rodents, or on the development of puberty in both sexes must show a real direct retardation of the sexual functions not accompanied by phenomena such as the formation of the corpora lutea in the ovary or hypertrophy of the mucous membrane of the uterus.  In making the extract, concentration of the active substance may be effected by removal of protein, by ultra-filtration or dialysis, by extraction with organic solvents, and by precipitation.  In one example, calves&#39; blood was centrifuged and a mouse test showed greater concentration of the hormone in the liquid portion; this portion was passed through an ultra-filter and tests showed greater concentration in the filtrate, which was worked up by concentration and filtration.  In a second example, young pigs&#39; serum was evaporated to dryness, powdered, extracted with alcohol, and the residue worked up by dialysis of an aqueous extract.  The active substance is present in the dialysate, and was precipitated with methyl alcohol, and the filter residue extracted with water.  In a third example, urine of healthy children was concentrated and filtered and the active substance obtained from the filtrate by precipitating with ethyl alcohol, and submitting an aqueous extract of the filter residue to dialysis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide nucleic acid molecules and proteins for identification, assessment, prevention, and therapy of ovarian cancer.  &lt;P&gt;SOLUTION: The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided. The invention also relates to cancer markers, which are listed in Table 1. The invention provides nucleic acids and proteins that are encoded by or correspond to the markers. The invention further provides antibodies, antibody derivatives and antibody fragments which bind specifically with such proteins and/or fragments of the proteins.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention proposes to use podophyllotoxin-β-D-glucopyranoside or 4&#39;-demethylpodophyllotoxin-β-D-glucopyranoside acetals of the general formula (I)   where R means OH or OCH 3  and R&#39; means alkyl, aryl or heterocyclic residue. Compounds are used for treatment and prophylaxis of amyloidosis states. Invention proposes method of treatment also. New agent and method of treatment suppress amyloid formation, do not cause severe adverse effects and suppress mutogen-induced proliferation of lymphocytes and synthesis of immunoglobulins. EFFECT: new agents indicated above, enhanced effectiveness. 8 cl, 1 tbl
PURPOSE:To form a gel compsn. having an arbitrary viscosity and good long- term stability and applicability, by blending a silicone oil, a silicon compd., an org. material-modified clay mineral and water. CONSTITUTION:A silicone oil, at least one member selected from among polyoxyalkylene-modified organopolysiloxanes (hereinafter referred to as polyether-modified silicone) of formulas I, II and III, an org. material-modified clay mineral and water are blended. In the formulas I, II and III, R group are methyl or part of R groups are phenyl; R&#39; is H, a 1-12C alkyl; p is 1-5; q is 2-3; x, m, n represents each, on an average, such a value that polyether- modified silicone contains 20-40wt% (excluding 20wt%) polyoxyalkylene group per molecule and has a viscosity of 5-3,000cSt at 25 deg.C. The gel compsn. is suitable for use as a base for cosmetics and pharmaceuticals and as wax for automobiles and furnishings.
PURPOSE:To provide a new compound having excellent bladder contraction suppressing action and useful as an agent for preventing and treating pollakiuria. CONSTITUTION:The compound of formula I (R&lt;1&gt; is H, halogen or lower alkoxy; R&lt;2&gt; and R&lt;3&gt; are H, lower alkyl or lower alkenyl), e.g. cis-5-(2-thienyl)-7- diethylamino-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol. The compound of formula I can be produced by reacting a carbonyl compound of formula II with a compound of formula III (M is alkali metal or MgX; X is halogen) optionally in the presence of a Lewis acid (e.g. stannic chloride) in a solvent (e.g. ether) under cooling or at room temperature. The compound is effective for the treatment and prevention of urination diseases of the lower urinary tract system (e.g. bladder and urethra) such as pollakiuria, bed-wetting, neurogenic bladder and incontinence of urine.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an apoptosis-inducing substance which contains a carotenoid pigment-containing extract originated from carotenoid-containing potato as an active ingredient, has greatly high safety, is more inexpensive than conventional anticancer agents, does not produce side effects, and can continuously be taken.  &lt;P&gt;SOLUTION: This apoptosis-inducing substance comprises a carotenoid pigment-containing extract extracted from a potato kind which is an ancestral potato kind for ordinary culture potato kinds, such as Solanum tuberosum ssp. tuberosam L. or Solanum phureja Juz. et Buk, a different culture potato kind, or a mated breeding kind based on them, improved in agronomic characters such as pigment concentration, disease resistance, yield or the like, and containing a carotenoid pigment in the flesh portion, has a yellow color tone of raw potato flesh portion in comparison with the Solanum tuberosum ssp. tuberosam L., and contains a carotenoid-based yellow pigment: zeaxanthin which is a main ingredient for forming the color tone of the flesh portion of the potato, in a concentration of ≥3 μg/g and has b&lt;SP&gt;*&lt;/SP&gt;of ≥30 in L&lt;SP&gt;*&lt;/SP&gt;, a&lt;SP&gt;*&lt;/SP&gt;and b&lt;SP&gt;*&lt;/SP&gt;color system and measured by a colorimeter, as a main ingredient for forming the color tone of the flesh portion.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a safe immunostimulator which can be used as a pharmaceutical or a food material, to provide a method for producing the same, and to provide a new method for using a coffee extract residue.  &lt;P&gt;SOLUTION: The immunostimulator contains a coffee extract as an active ingredient. Preferably, the coffee extract is an extract containing arabinogalactan. The immunostimulating activity is originated from the promotion of the proliferation of an immunocompetent cell such as a macrophage. The immunocompetent cell is preferably one selected from a macrophage like strain RAW264, a murine splenocyte, and a murine peritoneal macrophage. A composition containing the immunostimulator can be used as a composition such as a pharmaceutical composition, a food composition or a cosmetic composition.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a skin ointment having an improved skin-beautifying effect and capable of considerably improving the darkish skin by using a naturally occurring aescinol as a skin-beautifying component in combination with two specific kinds of surfactants. SOLUTION: The ointment contains an aescinol of formula (R&lt;1&gt; is H or OH; R&lt;2&gt; is pyranose residue) in combination with an anionic surfactant and another surfactant containing N atom in the molecule. The anionic surfactant preferably has a sulfonic acid group in the molecule. The other surfactant having N atom in the molecule is preferably an amine oxide-type semipolar surfactant. The molar ratio of these two kinds of surfactants is preferably 20:1 to 1:20, especially 10:1 to 1:10. The amount of the aescinol is preferably 0.001-20.0wt.% based on the total composition and the total amount of the surfactants is preferably 0.001-10.0wt.%. The aescinol of formula can be produced e.g. by the alkali decomposition of aescin existing in a seed of Aesculus hippocastanum.
PURPOSE:To obtain the subject compound of high safety, having excellent antineoplastic activity, useful as e.g. a carcinostatic agent, consisting of a cyclic hexapeptide compound having a specific amino acid sequence obtained by chemical modification of the extract from Rubia cordifolia L., a kind of medicinal herb. CONSTITUTION:RA-VII extracted from Rubia cordifolia L., a kind of medicinal herb, is dissolved in dichloromethane followed by adding an aqueous 50% NaOH solution, 3-bromopropene and tetra-n-butylammonium bromide to the resultant solution and then vigorously agitating the solution at room temperature. After a lapse of 5 hours, 3-bromobenzene and tetra-butylammonium bromide are further added to the solution followed by vigorous agitation at room temperature for 18hr. The resultant reaction liquor is then diluted with dichloromethane and then washed with water, 1N HCl and then saturated saline solution, and the resultant organic layer is dried with magnesium sulfate, filtered and then concentrated at reduced pressures, and the resultant concentrate is purified by silica gel column chromatography, thus obtaining the objective cyclic hexapeptide of the formula [R is formula R&lt;1&gt;CH2 (R&lt;1&gt; is 1-10C alkyl, aryl, etc.); X is O or S; Me is methyl].
PURPOSE:To provide a mutagen and carcinogen-resistant agent having an excellent suppressing activity against mutagen substances and added to drinks and foods to eliminate or weaken the mutability thereof by containing alginic acid having a specific weight-average mol.wt. as an active ingredient. CONSTITUTION:For example, a sea alga such as Hizikia fusiforme is ground, extracted with an alkali aqueous solution and mixed with an acid. The precipitates are subjected to a washing process using an organic solvent and other processes to provide a mutagen and carcinogen-resistant agent containing as an active ingredient alginic acid having a (B/A) ratio of &gt;=0.5 between a weight-average mol.wt. (A) determined with a gel permeation chromatography using pullulan as a standard and a weight-average mol.wt. (B) determined by a low angle laser light-scattering method with the gel permeation chromatography.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide new human sequence antibodies against human CTLA-4 and a method of treating human diseases, infections and other conditions by using these antibodies.  &lt;P&gt;SOLUTION: Provided are new human sequence antibodies against human CTLA-4, and a method for treating human diseases, infections and other conditions by using these antibodies. The therapeutically effective human sequence antibody is bonded to the CTLA-4 on the cell surface of a normal human cell. Also provided is a composition of a polyclonal antibody containing a number of human sequence antibodies specifically bonding to human CTLA-4. The composition of the antibody may contain at least about 2-1,000 different human sequence antibodies specifically bonding to human CTLA-4.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To obtain a bathing agent. composition containing alpha2-adrenergic suppressing medicine, capable of providing smoothness to skin and excellent in warm feeling of body. CONSTITUTION:This bathing agent composition contains &gt;=0.005wt.%, preferably 0.01-20wt.% of a beta-adrenergic suppressing medicine selected from yohimbine, phentolamine and ergotamine and theirs salts, etc., and further, inorganic salts (e.g. sodium sulfate), an organic acid (e.g. succinic acid), a carboxylic acid salt (e.g. sodium hydrogen carbonate) and an oily component (e.g. glyceride myristate) are preferably blended therein. The moist feeling of skin and warm feeling of body are further enhanced by combinedly using these ingredients. The concentration of the beta-adrenergic suppressing medicine used in bathing is preferably 0.01-200ppm. The bathing agent composition is used in an amount so as to provide 0.1-200ppm concentration of the p-adrenergic suppressing medicine at a time in bathing.
PURPOSE:To obtain a skin cosmetic having excellent effect to prevent the aging of the skin, e.g. skin-beautifying effect and effective in improving chapped skin and keratinized skin and quickening the turn-over of cuticle layer, by heat-treating tea leaf extract stored under anaerobic condition and compounding the treated extract to a cosmetic. CONSTITUTION:Air in a vessel containing raw tea leaves is thoroughly substituted with an inert gas such as CO2 or N2 and the vessel is closed to store the tea leaves under anaerobic condition. The stored tea leaves are steamed and/or dry-heat treated and the extract of the tea leaves is concentrated or, if necessary, purified by chromatography and concentrated under reduced pressure to obtain a solid (active component). The product is compounded in an amount of &gt;=0.1wt.%, preferably about 1-20wt.% in terms of solid to obtain the objective skin cosmetic exhibiting dermatic cell activation effect and blood flow promoting action in addition to rapid-acting effect to prevent the aging of skin. Furthermore, the cosmetic is effective by synergistic effect of moisture- retaining action and skin-beautifying action, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a novel hair cosmetic composition having improved moisture resistance and excellent stability and having a low volatile organic content.  &lt;P&gt;SOLUTION: The low-VOC (low volatile organic compound content) non-aerosol hair cosmetic composition contains a nonionically modified starch. The starch may be hydrolyzed, particularly enzymatically hydrolyzed. Further, the starch may be modified using ionic substituents. Use of such starches is novel and advantageous in that they provide clear solutions with good viscosities and good pump spray characteristics. Furthermore, the resultant composition provides a clear film which is not tack and has good stiffness and improved humidity resistance.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic composition containing a polysaccharide (levan) which exerts an excellent cell-proliferating, skin moisturizing and skin irritation- alleviating effects and is produced by microbes free of stability- and safety- related problems.  &lt;P&gt;SOLUTION: The cosmetic composition contains the polysaccharide (levan) which is isolated and purified from microbes known to produce levan using sucrose as a substrate, such as Rahnella aquatilis, Zymomonas mobilis and Pseudomonas aurantiaca. Levan is isolated and purified from media in which the microbes have been cultured, and dried. The levan extracted and purified from the microbes is shown to have an excellent skin-moisturizing effect through a measurement of its moisturizing effect, no toxicity through a cytotoxicity test and a skin irritation-alleviating effect through a skin irritation test employing a three-dimensional bioartificial skin and a human patch test. The composition is also shown to exert an excellent elasticity-enhancing effect via moisturization by directly applying it onto a human skin at a concentration equal to or higher than a predetermined level.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
Novel thienopyridones with antihypertensive activity have the formula I,   &lt;IMAGE&gt; I  wherein the ring A represents an optionally substituted thiophene ring; m is 0 or 1; n is 0, 1 or 2; R is lower alkyl and R1 is lower alkyl. The fused thieno-ring may carry one or two substituents. Formula I encompasses thieno[3,2-b]pyridones, thieno[3,4-b]pyridones and thieno[2,3-b]pyridones. Processes for preparing the novel thienopyridones and pharmaceutical compositions containing them are described. Pharmaceutically acceptable acid addition salts of the compounds of formula I are also described. The thienopyridones of formula I are antihypertensive agents and are also indicated for use in treating heart failure and ischaemic heart disease.
A stable composition of vitamin in a gelatin-urea medium is obtained by blending gelatin, urea and water at 0 DEG  C. to 80 DEG  C. until a uniform dispersion is obtained, admixing said dispersion with said vitamin and homogenizing, if desired, the resulting mixture until a uniform emulsion is obtained.  (By the term &#34;vitamin&#34; used herein is meant any or all of the well-known oil-soluble vitamins and their vitamin-active, pharmaceutically-acceptable salts and esters, whether prepared synthetically or obtained from natural sources.)  The obtained emulsion may be dehydrated by heating at 40 DEG  C. to 100 DEG  C. under reduced pressure and the resulting solid reduced to any desired particle size.  Alternatively, the emulsion may be blended at 0 DEG  C. to 90 DEG  C. with an inert, adsorbent carrier until granules are obtained to form a free-flowing, water-dispersible, oxygen-stable, dry adsorbate of vitamin.  Suitable adsorbents include soy flour, corn flour, rice flour, wheat flour, gelatin, lactose, mannitol and diatomaceous earth.  In the preparation of the emulsion, it is preferable to remove the materials employed from contact with oxygen, and when it is desired to convert the emulsion to the dehydrated or adsorbate form it is advantageous to add a plasticizer to the emulsion, e.g. glucose, corn syrup, propylene glycol or honey. Bacteriostats, e.g. zinc sulphate; yeast and mould inhibitors, e.g. sorbic acid; antirancidity and chelating agents, e.g. citric acid; and anti-oxidants may also be added to the emulsion.  The dehydrated and adsorbed emulsions may be treated according to the method described in Specification 993,138 to render them insoluble in water and gastric juice but soluble in intestinal fluid.  This may be achieved by adding to the emulsion a substance such as formaldehyde, glyoxal, dihydroxy-acetone or acetaldehyde.  Specified vitamins for use in the invention are Vitamin A, Vitamin A palmitate, Vitamin A acetate and Vitamins D, E and K.  The stable vitamin preparations of the invention may be employed in the preparation of stable multi-vitamin compositions, e.g. by combining with water-soluble vitamins and minerals, or may be incorporated in foods and animal feeds.ALSO:In food or animal feed is incorporated a stable vitamin composition in which the vitamin is dispersed in a gelatin-urea medium.  (&#34;Vitamin&#34; is any or all of the oil-soluble vitamins and their vitamin-active, pharmaceutically-acceptable salts and esters, synthetic or from natural sources.  Specified are Vitamin A, Vitamin A palmitate, Vitamin A acetate and Vitamins D, E and K).  The compositions in emulsion form may be granulated by drying and comminuting or by mixing with a carrier such as a cereal flour, soy flour, lactose or diatomaceous earth.  A plasticizer for gelatin, e.g. glucose, corn syrup, honey or propylene glycol may be incorporated in the composition. Specification 993,138 is referred to.
A method of causing irreversible damage to stealth virus infected cells, based on light induced toxic photosensitivity of abnormal, aggregated, intracellular materials present in the infected cells. The method of the present application specifically relates to the culturing of stealth viruses from an infected subject and determining the presence in the stealth virus infected culture of auto-fluorescent material. Auto-fluorescent material can also be found in cultures of bacteria that are infected with the patient&#39;s stealth virus. The cultured stealth virus infected cells are to be further tested for susceptibility to the cellular destructive effect of light therapy given at various wavelengths that are not injurious to normal uninfected cells. The presence of auto-fluorescent material in the stealth virus culture and the demonstration that exposure to light can cause damage to stealth virus infected cells, form the basis of therapy for stealth virus infected patients and animals. The therapy comprises exposing infected cells within a patient to light at the wavelengths that were shown to cause damage to cultured virus infected cells. Light mediated therapy is especially applicable as therapy for stealth virus associated cancers in which the stealth virus isolated from the cancer patient can be shown to induce the formation of auto-fluorescent material.